Mechanisms of Disease: apoptosis in heart failure-seeing hope in death

The loss of cardiomyocytes in failing or cardiomyopathic hearts is gradual and not accompanied by inflammation or major histomorphologic deformity. Apoptosis, therefore, seems to be the most logical mechanism of cell death. In this Review, Narula et al . discuss the role of apoptosis in systolic dys...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature clinical practice cardiovascular medicine 2006-12, Vol.3 (12), p.681-688
Hauptverfasser: Narula, Jagat, Haider, Nezam, Arbustini, Eloisa, Chandrashekhar, Y
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 688
container_issue 12
container_start_page 681
container_title Nature clinical practice cardiovascular medicine
container_volume 3
creator Narula, Jagat
Haider, Nezam
Arbustini, Eloisa
Chandrashekhar, Y
description The loss of cardiomyocytes in failing or cardiomyopathic hearts is gradual and not accompanied by inflammation or major histomorphologic deformity. Apoptosis, therefore, seems to be the most logical mechanism of cell death. In this Review, Narula et al . discuss the role of apoptosis in systolic dysfunction and heart failure, and in the development of novel strategies for the management of heart failure. Apoptosis or programmed cell death is an evolutionarily conserved process of cell death, wherein cells die without provoking significant inflammatory response. There is convincing evidence that apoptosis contributes to the progression of heart failure. Apoptosis occurs through a cascade of subcellular events including cytochrome c release into the cytoplasm and activation of proteolytic caspases. Activated caspases lead to fragmentation of cytoplasmic proteins, including contractile apparatus, to a variable extent. It is proposed that the release of cytochrome c from mitochondria and contractile protein loss in living heart muscle cells contributes to systolic dysfunction. Interestingly, despite extensive changes in the cytoplasm, nuclear damage, which is the final event in apoptosis, is rather infrequent in the failing heart. Since the nucleus remains unaffected and the genetic blueprint intact in cells with interrupted apoptosis, these heart muscle cells might be amenable to cytoplasmic reconstitution. This process of ' apoptosis interruptus ' could allow development of novel strategies to reverse or attenuate heart failure. Key Points Heart failure is a major cardiovascular health problem worldwide Heart failure is characterized by inexorable progression of systolic dysfunction through the process of adverse cardiac remodeling even after the initial, causal injury has abated Understanding the pathophysiological substrates of cardiac remodeling can help in the development of novel strategies for prevention, arrest and reversal of the remodeling process Apoptosis plays a pivotal role in heart failure. Although the apoptotic cascade is initiated, it does not complete in heart failure (' apoptosis interruptus ') Interrupted apoptosis reconfirms that heart failure could often be a reversible disease state, and offers an attractive target for management
doi_str_mv 10.1038/ncpcardio0710
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68176042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188726627</galeid><sourcerecordid>A188726627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-577b5dd5ba448cd7d06bf35a2c21b319aad562ce9da30121379cd12bb9d539953</originalsourceid><addsrcrecordid>eNp1kc1r3DAQxUVpyVdz7LUYCrk51Ui2ZfUWNh8NJOTSns1YGu8q2JIr2Yf89_Gym6YphDlomPnN44nH2Bfg58Bl_d2b0WC0LnAF_AM7AlXIvJCcf3zphVaH7DilR86lUrI-YIegQIiawxG7viezQe_SkLLQZZcuESb6keEYxikklzLnsw1hnLIOXT9HyhOR8-tsE0baLi3htPnMPnXYJzrdvyfs9_XVr9XP_O7h5nZ1cZebQsOUl0q1pbVli0VRG6ssr9pOliiMgFaCRrRlJQxpi5KDAKm0sSDaVttSal3KE3a20x1j-DNTmprBJUN9j57CnJqqBlXxQizgt__AxzBHv3hrQNWF0gpgS53vqDX21DjfhSmiWcrS4Ezw1LllfgF1rURVCbUc5LsDE0NKkbpmjG7A-NQAb7Z5NG_yWPivextzO5B9pfcBvDpIy8qvKf7j8x3F_cc8TksafxXfUs-Ko6M2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784797112</pqid></control><display><type>article</type><title>Mechanisms of Disease: apoptosis in heart failure-seeing hope in death</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Narula, Jagat ; Haider, Nezam ; Arbustini, Eloisa ; Chandrashekhar, Y</creator><creatorcontrib>Narula, Jagat ; Haider, Nezam ; Arbustini, Eloisa ; Chandrashekhar, Y</creatorcontrib><description>The loss of cardiomyocytes in failing or cardiomyopathic hearts is gradual and not accompanied by inflammation or major histomorphologic deformity. Apoptosis, therefore, seems to be the most logical mechanism of cell death. In this Review, Narula et al . discuss the role of apoptosis in systolic dysfunction and heart failure, and in the development of novel strategies for the management of heart failure. Apoptosis or programmed cell death is an evolutionarily conserved process of cell death, wherein cells die without provoking significant inflammatory response. There is convincing evidence that apoptosis contributes to the progression of heart failure. Apoptosis occurs through a cascade of subcellular events including cytochrome c release into the cytoplasm and activation of proteolytic caspases. Activated caspases lead to fragmentation of cytoplasmic proteins, including contractile apparatus, to a variable extent. It is proposed that the release of cytochrome c from mitochondria and contractile protein loss in living heart muscle cells contributes to systolic dysfunction. Interestingly, despite extensive changes in the cytoplasm, nuclear damage, which is the final event in apoptosis, is rather infrequent in the failing heart. Since the nucleus remains unaffected and the genetic blueprint intact in cells with interrupted apoptosis, these heart muscle cells might be amenable to cytoplasmic reconstitution. This process of ' apoptosis interruptus ' could allow development of novel strategies to reverse or attenuate heart failure. Key Points Heart failure is a major cardiovascular health problem worldwide Heart failure is characterized by inexorable progression of systolic dysfunction through the process of adverse cardiac remodeling even after the initial, causal injury has abated Understanding the pathophysiological substrates of cardiac remodeling can help in the development of novel strategies for prevention, arrest and reversal of the remodeling process Apoptosis plays a pivotal role in heart failure. Although the apoptotic cascade is initiated, it does not complete in heart failure (' apoptosis interruptus ') Interrupted apoptosis reconfirms that heart failure could often be a reversible disease state, and offers an attractive target for management</description><identifier>ISSN: 1743-4297</identifier><identifier>ISSN: 1759-5002</identifier><identifier>EISSN: 1743-4300</identifier><identifier>EISSN: 1759-5010</identifier><identifier>DOI: 10.1038/ncpcardio0710</identifier><identifier>PMID: 17122801</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; Apoptosis - drug effects ; Cardiac Imaging ; Cardiac Output, Low - metabolism ; Cardiac Output, Low - pathology ; Cardiac Output, Low - physiopathology ; Cardiac Surgery ; Cardiology ; Caspases - metabolism ; Cytochromes c - metabolism ; Energy Metabolism - drug effects ; Enzyme Activation - drug effects ; Humans ; Medicine ; Medicine &amp; Public Health ; Mitochondria, Heart - drug effects ; Mitochondria, Heart - metabolism ; Myocardial Contraction - drug effects ; Myocardium - metabolism ; Myocardium - pathology ; Protease Inhibitors - pharmacology ; review-article ; Ventricular Remodeling - drug effects</subject><ispartof>Nature clinical practice cardiovascular medicine, 2006-12, Vol.3 (12), p.681-688</ispartof><rights>Springer Nature Limited 2006</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-577b5dd5ba448cd7d06bf35a2c21b319aad562ce9da30121379cd12bb9d539953</citedby><cites>FETCH-LOGICAL-c491t-577b5dd5ba448cd7d06bf35a2c21b319aad562ce9da30121379cd12bb9d539953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17122801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Narula, Jagat</creatorcontrib><creatorcontrib>Haider, Nezam</creatorcontrib><creatorcontrib>Arbustini, Eloisa</creatorcontrib><creatorcontrib>Chandrashekhar, Y</creatorcontrib><title>Mechanisms of Disease: apoptosis in heart failure-seeing hope in death</title><title>Nature clinical practice cardiovascular medicine</title><addtitle>Nat Rev Cardiol</addtitle><addtitle>Nat Clin Pract Cardiovasc Med</addtitle><description>The loss of cardiomyocytes in failing or cardiomyopathic hearts is gradual and not accompanied by inflammation or major histomorphologic deformity. Apoptosis, therefore, seems to be the most logical mechanism of cell death. In this Review, Narula et al . discuss the role of apoptosis in systolic dysfunction and heart failure, and in the development of novel strategies for the management of heart failure. Apoptosis or programmed cell death is an evolutionarily conserved process of cell death, wherein cells die without provoking significant inflammatory response. There is convincing evidence that apoptosis contributes to the progression of heart failure. Apoptosis occurs through a cascade of subcellular events including cytochrome c release into the cytoplasm and activation of proteolytic caspases. Activated caspases lead to fragmentation of cytoplasmic proteins, including contractile apparatus, to a variable extent. It is proposed that the release of cytochrome c from mitochondria and contractile protein loss in living heart muscle cells contributes to systolic dysfunction. Interestingly, despite extensive changes in the cytoplasm, nuclear damage, which is the final event in apoptosis, is rather infrequent in the failing heart. Since the nucleus remains unaffected and the genetic blueprint intact in cells with interrupted apoptosis, these heart muscle cells might be amenable to cytoplasmic reconstitution. This process of ' apoptosis interruptus ' could allow development of novel strategies to reverse or attenuate heart failure. Key Points Heart failure is a major cardiovascular health problem worldwide Heart failure is characterized by inexorable progression of systolic dysfunction through the process of adverse cardiac remodeling even after the initial, causal injury has abated Understanding the pathophysiological substrates of cardiac remodeling can help in the development of novel strategies for prevention, arrest and reversal of the remodeling process Apoptosis plays a pivotal role in heart failure. Although the apoptotic cascade is initiated, it does not complete in heart failure (' apoptosis interruptus ') Interrupted apoptosis reconfirms that heart failure could often be a reversible disease state, and offers an attractive target for management</description><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Cardiac Imaging</subject><subject>Cardiac Output, Low - metabolism</subject><subject>Cardiac Output, Low - pathology</subject><subject>Cardiac Output, Low - physiopathology</subject><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Caspases - metabolism</subject><subject>Cytochromes c - metabolism</subject><subject>Energy Metabolism - drug effects</subject><subject>Enzyme Activation - drug effects</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mitochondria, Heart - drug effects</subject><subject>Mitochondria, Heart - metabolism</subject><subject>Myocardial Contraction - drug effects</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>Protease Inhibitors - pharmacology</subject><subject>review-article</subject><subject>Ventricular Remodeling - drug effects</subject><issn>1743-4297</issn><issn>1759-5002</issn><issn>1743-4300</issn><issn>1759-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1r3DAQxUVpyVdz7LUYCrk51Ui2ZfUWNh8NJOTSns1YGu8q2JIr2Yf89_Gym6YphDlomPnN44nH2Bfg58Bl_d2b0WC0LnAF_AM7AlXIvJCcf3zphVaH7DilR86lUrI-YIegQIiawxG7viezQe_SkLLQZZcuESb6keEYxikklzLnsw1hnLIOXT9HyhOR8-tsE0baLi3htPnMPnXYJzrdvyfs9_XVr9XP_O7h5nZ1cZebQsOUl0q1pbVli0VRG6ssr9pOliiMgFaCRrRlJQxpi5KDAKm0sSDaVttSal3KE3a20x1j-DNTmprBJUN9j57CnJqqBlXxQizgt__AxzBHv3hrQNWF0gpgS53vqDX21DjfhSmiWcrS4Ezw1LllfgF1rURVCbUc5LsDE0NKkbpmjG7A-NQAb7Z5NG_yWPivextzO5B9pfcBvDpIy8qvKf7j8x3F_cc8TksafxXfUs-Ko6M2</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Narula, Jagat</creator><creator>Haider, Nezam</creator><creator>Arbustini, Eloisa</creator><creator>Chandrashekhar, Y</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Mechanisms of Disease: apoptosis in heart failure-seeing hope in death</title><author>Narula, Jagat ; Haider, Nezam ; Arbustini, Eloisa ; Chandrashekhar, Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-577b5dd5ba448cd7d06bf35a2c21b319aad562ce9da30121379cd12bb9d539953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Cardiac Imaging</topic><topic>Cardiac Output, Low - metabolism</topic><topic>Cardiac Output, Low - pathology</topic><topic>Cardiac Output, Low - physiopathology</topic><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Caspases - metabolism</topic><topic>Cytochromes c - metabolism</topic><topic>Energy Metabolism - drug effects</topic><topic>Enzyme Activation - drug effects</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mitochondria, Heart - drug effects</topic><topic>Mitochondria, Heart - metabolism</topic><topic>Myocardial Contraction - drug effects</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>Protease Inhibitors - pharmacology</topic><topic>review-article</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Narula, Jagat</creatorcontrib><creatorcontrib>Haider, Nezam</creatorcontrib><creatorcontrib>Arbustini, Eloisa</creatorcontrib><creatorcontrib>Chandrashekhar, Y</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature clinical practice cardiovascular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Narula, Jagat</au><au>Haider, Nezam</au><au>Arbustini, Eloisa</au><au>Chandrashekhar, Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanisms of Disease: apoptosis in heart failure-seeing hope in death</atitle><jtitle>Nature clinical practice cardiovascular medicine</jtitle><stitle>Nat Rev Cardiol</stitle><addtitle>Nat Clin Pract Cardiovasc Med</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>3</volume><issue>12</issue><spage>681</spage><epage>688</epage><pages>681-688</pages><issn>1743-4297</issn><issn>1759-5002</issn><eissn>1743-4300</eissn><eissn>1759-5010</eissn><abstract>The loss of cardiomyocytes in failing or cardiomyopathic hearts is gradual and not accompanied by inflammation or major histomorphologic deformity. Apoptosis, therefore, seems to be the most logical mechanism of cell death. In this Review, Narula et al . discuss the role of apoptosis in systolic dysfunction and heart failure, and in the development of novel strategies for the management of heart failure. Apoptosis or programmed cell death is an evolutionarily conserved process of cell death, wherein cells die without provoking significant inflammatory response. There is convincing evidence that apoptosis contributes to the progression of heart failure. Apoptosis occurs through a cascade of subcellular events including cytochrome c release into the cytoplasm and activation of proteolytic caspases. Activated caspases lead to fragmentation of cytoplasmic proteins, including contractile apparatus, to a variable extent. It is proposed that the release of cytochrome c from mitochondria and contractile protein loss in living heart muscle cells contributes to systolic dysfunction. Interestingly, despite extensive changes in the cytoplasm, nuclear damage, which is the final event in apoptosis, is rather infrequent in the failing heart. Since the nucleus remains unaffected and the genetic blueprint intact in cells with interrupted apoptosis, these heart muscle cells might be amenable to cytoplasmic reconstitution. This process of ' apoptosis interruptus ' could allow development of novel strategies to reverse or attenuate heart failure. Key Points Heart failure is a major cardiovascular health problem worldwide Heart failure is characterized by inexorable progression of systolic dysfunction through the process of adverse cardiac remodeling even after the initial, causal injury has abated Understanding the pathophysiological substrates of cardiac remodeling can help in the development of novel strategies for prevention, arrest and reversal of the remodeling process Apoptosis plays a pivotal role in heart failure. Although the apoptotic cascade is initiated, it does not complete in heart failure (' apoptosis interruptus ') Interrupted apoptosis reconfirms that heart failure could often be a reversible disease state, and offers an attractive target for management</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>17122801</pmid><doi>10.1038/ncpcardio0710</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1743-4297
ispartof Nature clinical practice cardiovascular medicine, 2006-12, Vol.3 (12), p.681-688
issn 1743-4297
1759-5002
1743-4300
1759-5010
language eng
recordid cdi_proquest_miscellaneous_68176042
source MEDLINE; Nature; Alma/SFX Local Collection
subjects Animals
Apoptosis - drug effects
Cardiac Imaging
Cardiac Output, Low - metabolism
Cardiac Output, Low - pathology
Cardiac Output, Low - physiopathology
Cardiac Surgery
Cardiology
Caspases - metabolism
Cytochromes c - metabolism
Energy Metabolism - drug effects
Enzyme Activation - drug effects
Humans
Medicine
Medicine & Public Health
Mitochondria, Heart - drug effects
Mitochondria, Heart - metabolism
Myocardial Contraction - drug effects
Myocardium - metabolism
Myocardium - pathology
Protease Inhibitors - pharmacology
review-article
Ventricular Remodeling - drug effects
title Mechanisms of Disease: apoptosis in heart failure-seeing hope in death
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanisms%20of%20Disease:%20apoptosis%20in%20heart%20failure-seeing%20hope%20in%20death&rft.jtitle=Nature%20clinical%20practice%20cardiovascular%20medicine&rft.au=Narula,%20Jagat&rft.date=2006-12-01&rft.volume=3&rft.issue=12&rft.spage=681&rft.epage=688&rft.pages=681-688&rft.issn=1743-4297&rft.eissn=1743-4300&rft_id=info:doi/10.1038/ncpcardio0710&rft_dat=%3Cgale_proqu%3EA188726627%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784797112&rft_id=info:pmid/17122801&rft_galeid=A188726627&rfr_iscdi=true